相关实验视频
Updated: Jan 12, 2026

07:29
Intravascular Delivery of Biologics to the Rat Kidney
Published on: September 1, 2016
8.1K
单剂量,长效注射布普伦诺芬用于阿片类药物戒断治疗
Jeffrey S Kruk1, Judith L Fraser1, Prasun Datta1
1Centre for Addiction Medicine, Nepean Hospital, Kingswood, Australia.
Drug and alcohol review
|November 5, 2025
概括
长期作用的注射性布普伦诺芬 (LAIB) 显示出对那些没有对传统治疗反应的患者治疗阿片类药物戒断症状的承诺. 对于大多数患者来说,单一的LAIB剂量足够控制了戒断,这表明可能减少住院时间.
科学领域:
- 药理学 药理学是指药理学的学科.
- 成 药物 药物 药物 药物
- 公共卫生 公共卫生
背景情况:
- 长效注射性布普伦诺芬 (LAIB) 是一种用于澳大利亚阿片类药物依赖的新型阿片类抗体治疗 (OAT).
- 有限的研究存在于LAIB在管理阿片类药物戒断的有效性.
研究的目的:
- 调查LAIB在阿片类药物戒断管理中的作用.
- 为了评估患者的满意度和症状控制,使用LAIB进行戒断.
主要方法:
- 对接受一次LAIB剂量的五名患者的医院记录进行了回顾性分析.
- 患者已经失败了传统的戒断管理,不愿意开始或继续OAT.
主要成果:
- 收集了人口统计,阿片类药物使用和停留时间的数据.
- 在随访前和随访期间描述了患者的戒断症状.
- 大多数患者在社区中对单一的LAIB剂量来控制戒断症状表示满意.
结论:
- 在选择其他治疗失败的患者中,LAIB可能有效用于阿片类药物戒断管理.
- LAIB的药理动力学特征表明,在体内缓慢的药物断奶,可能会减少戒断症状和住院时间.
- 需要进一步的研究,但初步数据对LAIB在退出管理方面是令人鼓舞的.
相关概念视频
Opioid Analgesics: Synthetic and Semisynthetic Opioids
906
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
906
Insulin Formulations: Types and Delivery
638
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
638
Drugs for Treatment of Diarrhea-Predominant IBS
615
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
615
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
244
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
244
Drugs for Treatment of Constipation-Predominant IBS
688
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
688
Depolarizing Blockers: Pharmocokinetics
559
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
559

